Braun Stacey Associates Inc. Has $38.83 Million Stock Position in Eli Lilly and Company (NYSE:LLY)

Braun Stacey Associates Inc. lessened its stake in Eli Lilly and Company (NYSE:LLYFree Report) by 7.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 66,604 shares of the company’s stock after selling 5,265 shares during the period. Eli Lilly and Company accounts for 1.7% of Braun Stacey Associates Inc.’s portfolio, making the stock its 7th largest holding. Braun Stacey Associates Inc.’s holdings in Eli Lilly and Company were worth $38,825,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently bought and sold shares of the stock. Simon Quick Advisors LLC raised its position in shares of Eli Lilly and Company by 10.5% during the 4th quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock valued at $1,706,000 after acquiring an additional 278 shares during the last quarter. Clear Harbor Asset Management LLC bought a new stake in shares of Eli Lilly and Company during the 4th quarter valued at $363,000. Liontrust Investment Partners LLP bought a new stake in shares of Eli Lilly and Company during the 3rd quarter valued at $8,326,000. WASHINGTON TRUST Co raised its position in shares of Eli Lilly and Company by 16.5% during the 4th quarter. WASHINGTON TRUST Co now owns 18,892 shares of the company’s stock valued at $11,013,000 after acquiring an additional 2,671 shares during the last quarter. Finally, Armstrong Fleming & Moore Inc bought a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at $357,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 1.6 %

Shares of LLY stock opened at $776.31 on Thursday. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. The firm’s 50-day moving average is $745.17 and its 200-day moving average is $643.27. The stock has a market cap of $737.62 billion, a price-to-earnings ratio of 133.85, a PEG ratio of 1.68 and a beta of 0.34. Eli Lilly and Company has a 52-week low of $351.27 and a 52-week high of $800.78.

Eli Lilly and Company (NYSE:LLYGet Free Report) last released its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.19. The firm had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business’s revenue was up 28.1% on a year-over-year basis. During the same period in the prior year, the firm earned $2.09 EPS. Sell-side analysts predict that Eli Lilly and Company will post 12.42 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. JPMorgan Chase & Co. boosted their price target on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a report on Friday, March 15th. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Bank of America boosted their price target on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a report on Friday, March 1st. Morgan Stanley upped their target price on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research note on Friday, February 16th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $850.00 target price on shares of Eli Lilly and Company in a research note on Friday, March 22nd. Three research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $700.00.

View Our Latest Report on LLY

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the firm’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the transaction, the insider now directly owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 180,667 shares of company stock valued at $116,186,189 in the last three months. 0.13% of the stock is currently owned by company insiders.

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Featured Articles

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.